Biogen Inc. (NASDAQ:BIIB) Stock Position Raised by Machina Capital S.A.S.

Machina Capital S.A.S. lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 9.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,605 shares of the biotechnology company’s stock after acquiring an additional 461 shares during the quarter. Machina Capital S.A.S.’s holdings in Biogen were worth $857,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of BIIB. Grandfield & Dodd LLC boosted its position in shares of Biogen by 5.2% in the third quarter. Grandfield & Dodd LLC now owns 1,261 shares of the biotechnology company’s stock worth $244,000 after buying an additional 62 shares during the period. Quent Capital LLC boosted its position in shares of Biogen by 31.9% in the fourth quarter. Quent Capital LLC now owns 298 shares of the biotechnology company’s stock worth $46,000 after buying an additional 72 shares during the period. TD Private Client Wealth LLC boosted its position in shares of Biogen by 25.0% in the third quarter. TD Private Client Wealth LLC now owns 385 shares of the biotechnology company’s stock worth $75,000 after buying an additional 77 shares during the period. Principal Securities Inc. boosted its position in shares of Biogen by 30.1% in the fourth quarter. Principal Securities Inc. now owns 337 shares of the biotechnology company’s stock worth $52,000 after buying an additional 78 shares during the period. Finally, Huntington National Bank boosted its position in shares of Biogen by 3.5% in the third quarter. Huntington National Bank now owns 2,308 shares of the biotechnology company’s stock worth $447,000 after buying an additional 79 shares during the period. 87.93% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on BIIB shares. Canaccord Genuity Group decreased their target price on Biogen from $298.00 to $265.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. BMO Capital Markets cut their price objective on Biogen from $156.00 to $139.00 and set a “market perform” rating for the company in a report on Thursday, February 13th. Sanford C. Bernstein began coverage on Biogen in a report on Tuesday, February 11th. They set a “market perform” rating and a $160.00 price objective for the company. Bank Of America (Bofa) cut their price objective on Biogen from $178.00 to $163.00 and set a “neutral” rating for the company in a report on Tuesday, February 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Biogen in a report on Thursday, February 13th. Seventeen analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $213.33.

Biogen Trading Up 2.0 %

Biogen stock opened at $150.38 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. The business’s 50-day simple moving average is $143.98 and its 200-day simple moving average is $166.46. The firm has a market capitalization of $22.01 billion, a PE ratio of 13.44, a PEG ratio of 1.51 and a beta of 0.01. Biogen Inc. has a 52 week low of $128.51 and a 52 week high of $238.00.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. Equities research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.